Cytokines, stress, and depressive illness

It has been suggested that immune activation, and particularly increased activity of several cytokines, notably interleukin-1, interleukin-2, interleukin-6, tumor necrosis factor-alpha as well as their soluble receptors is characteristic of depression. Normalization of cytokine activity does not necessarily occur following successful antidepressant, suggesting that cytokines may be trait markers of depression, or simply represent bystander effects of the illness. The relationship between cytokines and depression is complicated as a variety factors could directly or indirectly influence cytokine activity. While cytokine elevations are most pronounced in severe (melancholic) depression, their activity may also be related to chronicity of illness, neurovegetative features of depression (altered sleep patterns, food intake, weight changes, fatigue or general activity), or the high stress perception characteristic of depression. Although, studies assessing cytokines in depressive populations are basically correlational in nature, patients receiving cytokine immunotherapy frequently show depressive symptoms, which may be attenuated by antidepressant medication, supporting a causal role for cytokines in depressive disorders. The processes underlying such outcomes remain to be established, but the affective changes may stem from the neuroendocrine and central neurochemical changes elicited by cytokines, as these are reminiscent of those associated thought to subserve depression.

[1]  J. Chambers,et al.  Effect of epinephrine-liberated pancreatic substance on uptake of alpha aminoisobutyric acid by isolated perfused rat liver. , 1972, Life sciences. Pt. 2: Biochemistry, general and molecular biology.

[2]  H. Anisman,et al.  Do early-life events permanently alter behavioral and hormonal responses to stressors? , 1998, International Journal of Developmental Neuroscience.

[3]  D. Revicki,et al.  Reliability and validity of a health-related quality of life battery for evaluating outpatient antidepressant treatment , 1992, Quality of Life Research.

[4]  R. Post,et al.  Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. , 1992, The American journal of psychiatry.

[5]  B. Bush,et al.  High-performance liquid chromatography of biogenic amines and metabolites in brain, cerebrospinal fluid, urine and plasma. , 1986, Journal of chromatography.

[6]  C. Plata-salamán,et al.  Pro-inflammatory and anti-inflammatory cytokine mRNA induction in the periphery and brain following intraperitoneal administration of bacterial lipopolysaccharide , 2001, Brain Research Bulletin.

[7]  D. Klein,et al.  Predictive value of symptoms of atypical depression for differential drug treatment outcome. , 1992, Journal of clinical psychopharmacology.

[8]  W. Banks,et al.  Differential transport of rat and human interleukin-1α across the blood–brain barrier and blood–testis barrier in rats , 2000, Brain Research.

[9]  J. Rybakowski,et al.  Interleukin‐6 Serum Levels in Depressed Patients before and after Treatment with Fluoxetine , 1995, Annals of the New York Academy of Sciences.

[10]  N. Rothwell Cytokines in the Nervous System , 1996, Neuroscience Intelligence Unit.

[11]  T. Smith,et al.  Major depressive disorder, alcoholism, and reduced natural killer cell cytotoxicity. Role of severity of depressive symptoms and alcohol consumption. , 1990, Archives of general psychiatry.

[12]  H. Miyaoka,et al.  Depression from interferon therapy in patients with hepatitis C. , 1999, The American journal of psychiatry.

[13]  H. Meltzer,et al.  Interleukin-1 beta: a putative mediator of HPA axis hyperactivity in major depression? , 1993, The American journal of psychiatry.

[14]  A K Manatunga,et al.  Paroxetine for the prevention of depression induced by high-dose interferon alfa. , 2001, The New England journal of medicine.

[15]  S. Cohen,et al.  Stress and immunity in humans: a meta‐analytic review. , 1993, Psychosomatic medicine.

[16]  A. Valentine,et al.  Neurological and Psychiatric Adverse Effects of Immunological Therapy , 1995 .

[17]  N. Rothwell,et al.  Cytokines and the nervous system II: actions and mechanisms of action , 1995, Trends in Neurosciences.

[18]  N. Rothwell Cytokines ‐ killers in the brain? , 1999 .

[19]  H. Anisman,et al.  Lymphocyte Subsets Associated With Major Depression and Dysthymia: Modification by Antidepressant Treatment , 1995, Psychosomatic medicine.

[20]  H. Anisman,et al.  Circulating Lymphocyte Subsets in Major Depression and Dysthymia With Typical or Atypical Features , 1998, Psychosomatic medicine.

[21]  T. Lundeberg,et al.  Activation of Vagal Afferents after Intravenous Injection of Interleukin-1β: Role of Endogenous Prostaglandins , 1998, The Journal of Neuroscience.

[22]  C. Plata-salamán,et al.  Neither acute nor chronic exposure to a naturalistic (predator) stressor influences the interleukin-1β system, tumor necrosis factor-α, transforming growth factor-β1, and neuropeptide mRNAs in specific brain regions , 2000, Brain Research Bulletin.

[23]  R. Roth,et al.  The determinants of stress-induced activation of the prefrontal cortical dopamine system. , 1990, Progress in brain research.

[24]  R. Dantzer,et al.  Lowered Serum Dipeptidyl Peptidase IV Activity is Associated with Depressive Symptoms and Cytokine Production in Cancer Patients Receiving Interleukin-2-Based Immunotherapy , 2001, Neuropsychopharmacology.

[25]  B. Prusoff,et al.  Scaling of life events. , 1971, Archives of general psychiatry.

[26]  H. Anisman,et al.  Interleukin-1β production in dysthymia before and after pharmacotherapy , 1999, Biological Psychiatry.

[27]  S. Maier,et al.  Timecourse and corticosterone sensitivity of the brain, pituitary, and serum interleukin-1β protein response to acute stress , 2000, Brain Research.

[28]  W. Banks,et al.  Human interleukin (IL) 1 alpha, murine IL-1 alpha and murine IL-1 beta are transported from blood to brain in the mouse by a shared saturable mechanism. , 1991, The Journal of pharmacology and experimental therapeutics.

[29]  R. Dantzer,et al.  Mechanisms of the behavioural effects of cytokines. , 1999, Advances in experimental medicine and biology.

[30]  E. Schmidt,et al.  Phenotypic Plasticity of CRF Neurons during Stress a , 1993, Annals of the New York Academy of Sciences.

[31]  P. MohanKumar,et al.  Interleukin-1 stimulates the release of dopamine and dihydroxyphenylacetic acid from the hypothalamus in vivo. , 1991, Life sciences.

[32]  E. Schmidt,et al.  Interleukin‐1‐Induced Plasticity of Hypothalamic CRH Neurons and Long‐Term Stress Hyperresponsiveness a , 1998, Annals of the New York Academy of Sciences.

[33]  T. Patterson,et al.  Reduction of immune function in life stress and depression , 1990, Biological Psychiatry.

[34]  M. Demitrack,et al.  Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. , 1991, The Journal of clinical endocrinology and metabolism.

[35]  P. Müller-Preuss,et al.  Effect of bacterial endotoxin and interleukin-1 beta on hippocampal serotonergic neurotransmission, behavioral activity, and free corticosterone levels: an in vivo microdialysis study , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[36]  R. Dantzer,et al.  Timing and Specificity of the Cognitive Changes Induced by Interleukin-2 and Interferon-&agr; Treatments in Cancer Patients , 2001, Psychosomatic medicine.

[37]  C. Weisse,et al.  Depression and immunocompetence: a review of the literature. , 1992, Psychological bulletin.

[38]  E. Bosmans,et al.  Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. , 1997, Cytokine.

[39]  H. Anisman,et al.  Further evidence for the depressive effects of cytokines: Anhedonia and neurochemical changes , 2002, Brain, Behavior, and Immunity.

[40]  H. Anisman,et al.  Interleukin-2 decreases accumbal dopamine efflux and responding for rewarding lateral hypothalamic stimulation , 1996, Brain Research.

[41]  Bruce S. McEwen,et al.  INDUCTION OF CORTICOTROPIN-RELEASING HORMONE GENE EXPRESSION BY GLUCOCORTICOIDS: IMPLICATION FOR UNDERSTANDING THE STATES OF FEAR AND ANXIETY AND ALLOSTATIC LOAD , 1998, Psychoneuroendocrinology.

[42]  S. Kennedy,et al.  Low plasma cortisol in bulimia nervosa patients with reversed neurovegetative symptoms of depression , 1997, Biological Psychiatry.

[43]  M. Maes,et al.  Major depression and activation of the inflammatory response system. , 1999, Advances in experimental medicine and biology.

[44]  H. Anisman,et al.  Sensitization to the Effects of Tumor Necrosis Factor-α: Neuroendocrine, Central Monoamine, and Behavioral Variations , 1999, The Journal of Neuroscience.

[45]  M. Irwin,et al.  Immune correlates of depression. , 1999, Advances in experimental medicine and biology.

[46]  E. Bosmans,et al.  Plasma levels of interleukin-6, interleukin-10, and interleukin-1 receptor antagonist in depression: comparison between the acute state and after remission. , 2000, Polish journal of pharmacology.

[47]  A. Leon,et al.  Measurement of Severity and Treatment Response in Dysthymia , 1993 .

[48]  S. Cohen,et al.  Depression and immunity: a meta-analytic review. , 1993, Psychological bulletin.

[49]  H. Anisman,et al.  Lipopolysaccharide, central in vivo biogenic amine variations, and anhedonia , 1998, Neuroreport.

[50]  Joseph E LeDoux Emotion: clues from the brain. , 1995, Annual review of psychology.

[51]  C. Nemeroff,et al.  The corticotropin-releasing factor (CRF) hypothesis of depression: new findings and new directions. , 1996, Molecular psychiatry.

[52]  S. Maier,et al.  Cytokines for psychologists: implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. , 1998, Psychological review.

[53]  E. Bosmans,et al.  Depression‐related disturbances in mitogen‐induced lymphocyte responses and interleukin‐1β and soluble interleukin‐2 receptor production , 1991, Acta psychiatrica Scandinavica.

[54]  M. Hamilton,et al.  Development of a rating scale for primary depressive illness. , 1967, The British journal of social and clinical psychology.

[55]  H. Anisman,et al.  Effects of interleukin-1β and mild stress on alterations of norepinephrine, dopamine and serotonin neurotransmission: a regional microdialysis study , 1997, Brain Research.

[56]  H. Anisman,et al.  Treatment of primary dysthymia with group cognitive therapy and pharmacotherapy: clinical symptoms and functional impairments. , 1999, The American journal of psychiatry.

[57]  A. Caraceni,et al.  Neuropsychological and neurophysiological assessment of the central effects of interleukin-2 administration. , 1993, European journal of cancer.

[58]  H. Anisman,et al.  Lymphocyte proliferation among major depressive and dysthymic patients with typical or atypical features. , 2000, Journal of Affective Disorders.

[59]  M. Ackenheil,et al.  Psychoneuroimmunology and the cytokine action in the CNS: Implications for psychiatric disorders , 1998, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[60]  H. Anisman,et al.  Influence of interleukin-1β on exploratory behaviors, plasma ACTH, corticosterone, and central biogenic amines in mice , 1998, Psychopharmacology.

[61]  F. Bloom,et al.  Psychopharmacology: The Fourth Generation of Progress , 1995 .

[62]  D. Rubinow,et al.  The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. , 1987, Annals of internal medicine.

[63]  S. Maier,et al.  Exposure to Acute Stress Induces Brain Interleukin-1β Protein in the Rat , 1998, The Journal of Neuroscience.

[64]  H. Anisman,et al.  Multisystem Regulation of Performance Deficits Induced by Stressors , 1991 .

[65]  R. Yirmiya Endotoxin produces a depressive-like episode in rats , 1996, Brain Research.

[66]  R. Adams,et al.  Coping behavior in depression: report on a new scale. , 1984, Behaviour research and therapy.

[67]  R. Dantzer,et al.  Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  M. Åsberg,et al.  A New Depression Scale Designed to be Sensitive to Change , 1979, British Journal of Psychiatry.

[69]  L C Harrison,et al.  Diurnal rhythmicity of human cytokine production: a dynamic disequilibrium in T helper cell type 1/T helper cell type 2 balance? , 1997, Journal of immunology.

[70]  J. Ceuppens,et al.  More exact quantification of interleukin-2 production by addition of anti-Tac monoclonal antibody to cultures of stimulated lymphocytes. , 1987, Journal of immunological methods.

[71]  Takashi Yamaguchi,et al.  Immobilization stress induces interleukin-1β mRNA in the rat hypothalamus , 1991, Neuroscience Letters.

[72]  H. Anisman,et al.  Anhedonic and anxiogenic effects of cytokine exposure. , 1999, Advances in experimental medicine and biology.

[73]  H. Anisman,et al.  Variations of nucleus accumbens dopamine and serotonin following systemic interleukin-1, interleukin-2 or interleukin-6 treatment , 1999, Neuroscience.

[74]  A. Reichenberg,et al.  Cytokines, "depression due to a general medical condition," and antidepressant drugs. , 1999, Advances in experimental medicine and biology.

[75]  T. Smith,et al.  Electroencephalographic sleep and natural killer activity in depressed patients and control subjects. , 1992, Psychosomatic medicine.

[76]  A. Dunn,et al.  Peripheral administration of interleukin-1 increases extracellular concentrations of norepinephrine in rat hypothalamus: Comparison with plasma corticosterone , 1996, Psychoneuroendocrinology.

[77]  H. Anisman,et al.  Time-dependent sensitization of corticotropin-releasing hormone, arginine vasopressin and c-fos immunoreactivity within the mouse brain in response to tumor necrosis factor-α , 2001, Neuroscience.

[78]  R. Dantzer,et al.  Cytokine Actions on Behavior , 1996 .

[79]  H. Anisman,et al.  Central monoamine and plasma corticosterone changes induced by a bacterial endotoxin: sensitization and cross‐sensitization effects , 2001, The European journal of neuroscience.

[80]  A. Turnbull,et al.  Cytokine Effects on Neuroendocrine Axes: Influence of Nitric Oxide and Carbon Monoxide , 1996 .

[81]  S. Kasper,et al.  Abnormal pituitary-adrenal responses to corticotropin-releasing hormone in patients with seasonal affective disorder: clinical and pathophysiological implications. , 1991, The Journal of clinical endocrinology and metabolism.

[82]  D. Klein,et al.  Antidepressant specificity in atypical depression. , 1988, Archives of general psychiatry.

[83]  L. Träskman-bendz,et al.  Increased soluble interleukin‐2 receptor concentrations in suicide attempters , 1993, Acta psychiatrica Scandinavica.

[84]  T. Harris,et al.  Social Origins of Depression: A Study of Psychiatric Disorder in Women , 1979 .

[85]  A. Beck,et al.  An inventory for measuring depression. , 1961, Archives of general psychiatry.

[86]  R. Lazarus,et al.  Comparison of two modes of stress measurement: Daily hassles and uplifts versus major life events , 1981, Journal of Behavioral Medicine.

[87]  A. Dunn Endotoxin-induced activation of cerebral catecholamine and serotonin metabolism: comparison with interleukin-1. , 1992, The Journal of pharmacology and experimental therapeutics.

[88]  J. Blalock,et al.  The syntax of immune-neuroendocrine communication. , 1994, Immunology today.

[89]  H. Meltzer,et al.  Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression , 1993, Psychiatry Research.

[90]  C. Plata-salamán,et al.  Cytokine interactions and cytokine balance in the brain: relevance to neurology and psychiatry , 1999, Molecular Psychiatry.

[91]  P. Sawchenko,et al.  A functional anatomical analysis of central pathways subserving the effects of interleukin-1 on stress-related neuroendocrine neurons , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[92]  Bruce Mcewen,et al.  Stress, Adaptation, and Disease: Allostasis and Allostatic Load , 1998, Annals of the New York Academy of Sciences.

[93]  B. Leonard,et al.  Changes in immunoglobulin, complement and acute phase protein levels in the depressed patients and normal controls. , 1994, Journal of affective disorders.

[94]  E. Bosmans,et al.  Evidence for a systemic immune activation during depression: results of leukocyte enumeration by flow cytometry in conjunction with monoclonal antibody staining , 1992, Psychological Medicine.

[95]  G. Asnis,et al.  Biological and clinical validation of atypical depression , 1996, Psychiatry Research.

[96]  H. Anisman,et al.  The Impact of Stressors on Immune and Central Neurotransmitter Activity: Bidirectional Communication , 1993, Reviews in the neurosciences.

[97]  V. Arolt,et al.  Cytokine Production and Serum Proteins in Depression , 1995, Scandinavian journal of immunology.

[98]  M. Wong,et al.  The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection , 1999, Molecular Psychiatry.

[99]  S. Rivest,et al.  Stress and Interleukin‐1 β‐Induced Activation of c‐fos, NGFI‐B ann CRF Gene Expression in the Hypothalamic PVN: Comparison Between Sprague‐Dawley, Fisher‐344 and Lewis Rats , 1994, Journal of neuroendocrinology.

[100]  Michael Davis,et al.  Neurotransmission in the rat amygdala related to fear and anxiety , 1994, Trends in Neurosciences.

[101]  R. S. Smith The macrophage theory of depression. , 1991, Medical hypotheses.

[102]  H. Anisman,et al.  Behavioral and neurochemical consequences of lipopolysaccharide in mice: anxiogenic-like effects , 1999, Brain Research.

[103]  P. MohanKumar,et al.  Systemic administration of interleukin-1 stimulates norepinephrine release in the paraventricular nucleus. , 1993, Life sciences.

[104]  H. Meltzer,et al.  Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. , 1995, Journal of affective disorders.

[105]  A. Sluzewska,et al.  Indicators of immune activation in depressed patients. , 1999, Advances in experimental medicine and biology.

[106]  M. Berk,et al.  Acute phase proteins in major depression. , 1997, Journal of psychosomatic research.

[107]  Satoshi Obana,et al.  Differential Effects of Neuropeptides on Cytokine Production by Mouse Helper T Cell Subsets , 1998, Neuroimmunomodulation.

[108]  N. Varney,et al.  Psychopharmacology: The Fourth Generation of Progress. , 1996 .

[109]  E. Schmidt,et al.  Interleukin-1-induced long-lasting changes in hypothalamic corticotropin-releasing hormone (CRH)--neurons and hyperresponsiveness of the hypothalamus-pituitary-adrenal axis , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[110]  S. Lightman,et al.  Early-life exposure to endotoxin alters hypothalamic-pituitary-adrenal function and predisposition to inflammation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[111]  Michael Maes,et al.  Evidence for an immune response in major depression: A review and hypothesis , 1995, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[112]  M. Wong,et al.  Corticotropin Releasing Hormone in the Pathophysiology of Melancholic and Atypical Depression and in the Mechanism of Action of Antidepressant Drugs , 1995, Annals of the New York Academy of Sciences.

[113]  H. Anisman,et al.  Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features , 1999, Molecular Psychiatry.

[114]  S. Maier,et al.  Cytokine-to-brain communication: a review & analysis of alternative mechanisms. , 1995, Life sciences.